May 2008
Volume 49, Issue 13
Free
ARVO Annual Meeting Abstract  |   May 2008
Intravitreal Bevacizumab as Primary Treatment for Subfoveal Choroidal Neovascularization Secondary to Posterior Uveitis
Author Affiliations & Notes
  • L. Sobrin
    Harvard Med Mass Eye & Ear Infirmary, Boston, Massachusetts
    Retina/Uveitis,
  • I. K. Kim
    Harvard Med Mass Eye & Ear Infirmary, Boston, Massachusetts
    Retina,
  • Footnotes
    Commercial Relationships  L. Sobrin, None; I.K. Kim, None.
  • Footnotes
    Support  NIH Grant EY16335-02
Investigative Ophthalmology & Visual Science May 2008, Vol.49, 4737. doi:https://doi.org/
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      L. Sobrin, I. K. Kim; Intravitreal Bevacizumab as Primary Treatment for Subfoveal Choroidal Neovascularization Secondary to Posterior Uveitis. Invest. Ophthalmol. Vis. Sci. 2008;49(13):4737. doi: https://doi.org/.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: : To report the efficacy and safety of intravitreal bevacizumab (Avastin) as the primary treatment for subfoveal choroidal neovascularization (CNV) due to posterior uveitis.

Methods: : Intravitreal bevacizumab (1.25 mg/0.05 ml) was injected into three eyes of three patients with previously untreated CNV secondary to posterior uveitis in this consecutive, interventional, non-comparative case series. Snellen best-corrected visual acuity (BCVA), level of intraocular inflammation, central macular thickness on optical coherence tomography, fluorescein angiographic characteristics, and complications were examined before and after treatment. The minimum follow-up time was five months.

Results: : The underlying diagnoses were punctate inner choroiditis (PIC) in two patients and multifocal choroiditis (MFC) in one patient. Mean follow-up was 12 months (range, 5 - 18 months). All patients had quiescent inflammatory disease at the time of injection and throughout the follow-up period. No patients were on immunomodulatory therapy for their underlying diagnoses. Two eyes received a single intravitreal bevacizumab injection and one eye received three injections. BCVA improved by two or more Snellen acuity lines in the two PIC patients (from 20/125 to 20/25 in one patient and from 20/125 to 20/60 in the second patient). BCVA worsened by one line in the patient with MFC (from 20/200 to 20/320). Central macular thickness improved in all patients from a pre-injection mean of 413 microns (range, 402 - 425 microns) to a post-injection mean of 258 microns (range, 203 - 324 microns). Leakage from the CNV decreased in all eyes. No injection complications were observed.

Conclusions: : : In this small series of eyes with limited follow-up, intravitreal bevacizumab seems to be potentially efficacious and safe in eyes with subfoveal CNV secondary to posterior uveitis. Further evaluation in larger series with longer follow-up is needed to assess the long-term efficacy and safety in such cases.

Keywords: chorioretinitis • choroid: neovascularization • drug toxicity/drug effects 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×